Drug and asset intelligence for Oxymorphone Hydrochloride with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Hikma →

Recent signals(1)

StrategyJune 29, 2026

Hikma's ANDA090964 for Oxymorphone Hydrochloride Receives AP Status

Hikma's Abbreviated New Drug Application (ANDA090964) for Oxymorphone Hydrochloride has received an Approval Pending (AP) status.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Hikma — Oxymorphone Hydrochloride

Monitor the final approval status and market launch timeline for ANDA090964.

June 29, 2026 · N/A

Topline Data

— Oxymorphone Hydrochloride

Monitor for market launch details and any subsequent competitive responses from other opioid manufacturers.

June 29, 2026 · N/A

Topline Data

Hikma — Oxymorphone Hydrochloride

Monitor market response and sales performance of Hikma's Oxymorphone Hydrochloride post-launch.

June 25, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Opioid →

Pain Management →

Pain Management · Opioid →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.